NAD+ Injectable Vials Recalled for Sterility Assurance Deficiency
NAD+ 200mg/ml vials from Tailor Made Compounding are recalled nationwide due to lack of assurance of sterility (Lot#07192307A2, BUD 11/18/2023). Consumers should discontinue use and consult their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is FDA Class II without reported illnesses or hospitalizations. The lack of sterility assurance in an injectable product presents risk of serious harm, but no injuries have been reported, fitting the 'risk-of-harm products where injury has not yet been reported' criterion for Score 3 (High).
Plain-English summary
Tailor Made Compounding (TMC Acquisitions LLC) has recalled NAD+ 200mg/ml injectable vials distributed nationwide. The product is supplied in 10ml vials with Lot#07192307A2 and expiration date 11/18/2023, with a total of 99 vials affected.
The recall is due to lack of assurance of sterility in the compounded drug vials. Sterility is critical for injectable products to prevent serious infections.
Consumers and healthcare providers who have received or possess vials from this lot should discontinue use immediately. Affected patients should contact their healthcare provider for guidance on appropriate alternatives. Healthcare providers, clinics, and pharmacies should verify receipt of product from this lot and remove it from circulation.
The recalled product
- Product
- NAD+ 200mg/ml, 10ml vials, Tailor Made Compounding.
- Manufacturer
- TMC Acquisitions LLC dba Tailor Made Compounding
- Category
- Drug — Compounded Injectable
- Hazard
- sterility-defect
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 07192307A2
- BUD: 11/18/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27